Special Sections: Letters to the Editor

Adherence to Urate-Lowering Therapy

Authors: Richard O. Day MD, FRACP

Abstract

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

References1. Riedel AA, Nelson M, Joseph-Ridge N, et al. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol 2004;31:1575–1581.RiedelAA]]NelsonM]]Joseph-RidgeN&etal;Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims.J Rheumatol2004311575-15812. Solomon D, Avorn J, Levin R, et al. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis 2008;57:609–613.SolomonD]]AvornJ]]LevinR&etal;Uric acid lowering therapy: prescribing patterns in a large cohort of older adults.Ann Rheum Dis200857609-6133. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76:47–56.HandeKR]]NooneRM]]StoneWJSevere allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency.Am J Med19847647-56